Document Detail

Differences in rhodamine-123 efflux in B-type chronic lymphocytic leukemia suggest possible gender and stage variations in drug-resistance gene activity.
MedLine Citation:
PMID:  9671131     Owner:  NLM     Status:  MEDLINE    
Peripheral blood samples from 61 patients (36 male, 25 female) with all stages of B-type chronic lymphocytic leukemia (CLL) were studied for MDR1 phenotype using monoclonal antibodies and rhodamine-123 dye exclusion, a functional assay of MDR1 expression. The duration of the disease varied from 1 month to 22 years at the time of initial study. Overall, 74% of the patients were positive for rhodamine-123 exclusion. When analyzed by gender, significantly more men than women were positive (89% versus 48%, p<0.001). There were more positive men than women for every stage of the disease. Female patients were found to be either MDR1 phenotype positive or negative at any stage of the disease. In contrast, all male patients with early (stages 0-II) disease were MDR1 phenotype positive. One early-stage (stage II) male patient converted from rhodamine-efflux positive to rhodamine-efflux negative as he progressed from stage-II to stage-IV disease. We suggest that some of the differences in disease biology of male versus female CLL patients (women having a more benign course) may be due to gender-dependent differences in drug-resistance gene activity, including MDR1. Our results also emphasize the need to take into account gender in evaluating the clinical course of patients with CLL.
H Steiner; A Polliack; C Kimchi-Sarfaty; D Libster; E Fibach; D Rund
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Annals of hematology     Volume:  76     ISSN:  0939-5555     ISO Abbreviation:  Ann. Hematol.     Publication Date:  1998 May 
Date Detail:
Created Date:  1998-08-12     Completed Date:  1998-08-12     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9107334     Medline TA:  Ann Hematol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  189-94     Citation Subset:  IM    
Hematology Department, Hadassah University Hospital and Hebrew University Medical School, Ein Kerem, Jerusalem, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antibodies, Monoclonal
Antineoplastic Agents / administration & dosage
B-Lymphocytes / drug effects*
Coloring Agents / pharmacokinetics*
Drug Resistance, Neoplasm / genetics*
Genes, MDR / genetics
Leukemia, Lymphocytic, Chronic, B-Cell / genetics*,  pathology
Middle Aged
Neoplasm Staging
P-Glycoprotein / analysis,  immunology
Rhodamine 123
Rhodamines / pharmacokinetics*
Sex Characteristics
Time Factors
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antineoplastic Agents; 0/Coloring Agents; 0/P-Glycoprotein; 0/Rhodamines; 62669-70-9/Rhodamine 123

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  High-dose chemotherapy with autologous stem cell support in poor-risk germ cell tumors.
Next Document:  Expression of genes implicated in multidrug resistance in acute lymphoblastic leukemia in India.